Skip to main content

Compare Stocks

Date Range: 

 Zosano PharmaLeap TherapeuticsAprea TherapeuticsMoleculin BiotechCyclerion Therapeutics
SymbolNASDAQ:ZSANNASDAQ:LPTXNASDAQ:APRENASDAQ:MBRXNASDAQ:CYCN
Price Information
Current Price$0.74$1.57$4.12$3.30$2.94
52 Week RangeBuyBuyHoldBuyN/A
MarketRank™
Overall Score1.41.51.61.21.3
Analysis Score3.53.53.13.50.0
Community Score2.92.61.82.72.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.82.50.03.3
Earnings & Valuation Score0.60.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyN/A
Consensus Price Target$2.17$5.38$14.25$15.00N/A
% Upside from Price Target193.98% upside242.36% upside245.87% upside354.55% upsideN/A
Trade Information
Market Cap$78.66 million$93.68 million$87.29 million$93.87 million$100.35 million
Beta2.981.350.12.112.2
Average Volume8,427,470759,1481,275,9122,314,016722,214
Sales & Book Value
Annual RevenueN/AN/AN/AN/A$4.51 million
Price / SalesN/AN/AN/AN/A22.25
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.40 per share($0.07) per share$5.92 per share$0.34 per share$3.56 per share
Price / BookN/AN/AN/AN/A0.83
Profitability
Net Income$-37,590,000.00$-32,900,000.00$-28,060,000.00$-13,200,000.00$-123,010,000.00
EPS($2.29)($1.47)($4.67)($0.32)N/A
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/A-2,322.42%
Return on Equity (ROE)-227.55%-89.24%-47.95%-113.25%-105.55%
Return on Assets (ROA)-79.80%-70.07%-42.96%-63.20%-57.77%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio0.68%8.70%7.49%4.44%4.31%
Quick Ratio0.68%8.70%7.49%4.44%4.31%
Ownership Information
Institutional Ownership Percentage10.07%41.90%79.31%4.82%68.17%
Insider Ownership Percentage6.10%25.89%52.20%8.30%10.70%
Miscellaneous
Employees4530111034
Shares Outstanding106.73 million59.67 million21.19 million28.44 million34.13 million
Next Earnings Date8/5/2021 (Estimated)8/12/2021 (Estimated)8/10/2021 (Estimated)8/11/2021 (Estimated)5/17/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
If You’re Not Bullish on Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Now, You’ll Kick Yourself LaterIf You’re Not Bullish on Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Now, You’ll Kick Yourself Later
stocksregister.com - May 10 at 3:25 PM
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) CEO Peter M. Hecht Buys 302,000 SharesCyclerion Therapeutics, Inc. (NASDAQ:CYCN) CEO Peter M. Hecht Buys 302,000 Shares
americanbankingnews.com - May 10 at 11:44 AM
The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More SharesThe CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares
finance.yahoo.com - May 9 at 1:26 PM
Friday 5/7 Insider Buying Report: CYCN, WYFriday 5/7 Insider Buying Report: CYCN, WY
nasdaq.com - May 7 at 1:38 PM
Stock Alert: Cyclerion Therapeutics Jumps 13% As CEO Raises Stake In Co.Stock Alert: Cyclerion Therapeutics Jumps 13% As CEO Raises Stake In Co.
nasdaq.com - May 7 at 1:38 PM
Cyclerion Therapeutics Inc (CYCN) CEO Peter M Hecht Bought $1.7 million of SharesCyclerion Therapeutics Inc (CYCN) CEO Peter M Hecht Bought $1.7 million of Shares
uk.finance.yahoo.com - May 7 at 8:36 AM
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) CEO Purchases $687,000.00 in StockCyclerion Therapeutics, Inc. (NASDAQ:CYCN) CEO Purchases $687,000.00 in Stock
americanbankingnews.com - May 6 at 11:32 PM
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares Look Bullish in 2021Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares Look Bullish in 2021
stocksregister.com - May 1 at 5:36 PM
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock Forecast 2021: $4 Per Share With Bullish SignsCyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock Forecast 2021: $4 Per Share With Bullish Signs
marketingsentinel.com - April 27 at 1:41 PM
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline ProgressCyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
finance.yahoo.com - April 27 at 1:41 PM
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of DirectorsCyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
finance.yahoo.com - April 26 at 8:22 AM
Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) a Suitable Stock for New Investors Now?Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) a Suitable Stock for New Investors Now?
stocksregister.com - April 24 at 1:06 PM
Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor ConferenceCyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
finance.yahoo.com - April 21 at 9:38 AM
Cyclerion Therapeutics to Host Pipeline Update WebinarCyclerion Therapeutics to Host Pipeline Update Webinar
finance.yahoo.com - April 20 at 8:41 AM
Aavantibio taps Wright as chief medical officerAavantibio taps Wright as chief medical officer
pehub.com - March 30 at 11:51 AM
Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.s (NASDAQ:CYCN) Shares?Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?
finance.yahoo.com - March 22 at 8:57 AM
IXICO selected by Cyclerion for new Alzheimers disease studyIXICO selected by Cyclerion for new Alzheimer's disease study
prnewswire.com - March 2 at 7:13 AM
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate UpdateCyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
finance.yahoo.com - February 25 at 8:14 AM
CYCN Stock Price Increases Over 25%: Why It HappenedCYCN Stock Price Increases Over 25%: Why It Happened
pulse2.com - February 4 at 5:28 PM
Cyclerion Therapeutics Announces Clinical and Scientific Advisory BoardsCyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
finance.yahoo.com - January 25 at 8:38 AM
How Much Did Cyclerion Therapeutics(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year?How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year?
finance.yahoo.com - January 21 at 10:30 AM
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C.Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C.
apnews.com - January 5 at 10:00 AM
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect ConferenceCyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
finance.yahoo.com - January 4 at 7:30 AM
Cyclerion Announces Leadership TransitionsCyclerion Announces Leadership Transitions
finance.yahoo.com - December 21 at 12:23 PM
Cyclerion Therapeutics, Inc. (CYCN)Cyclerion Therapeutics, Inc. (CYCN)
finance.yahoo.com - December 6 at 9:38 PM
DateCompanyBrokerageAction
3/22/2021Zosano PharmaMaxim GroupBoost Price Target
11/25/2020Zosano PharmaHC WainwrightLower Price Target
10/22/2020Zosano PharmaBTIG ResearchLower Price Target
11/15/2019Zosano PharmaCantor FitzgeraldLower Price Target
3/23/2021Leap TherapeuticsRaymond JamesSet Price Target
7/19/2020Leap TherapeuticsLADENBURG THALM/SH SHReiterated Rating
6/29/2020Leap TherapeuticsPiper SandlerInitiated Coverage
2/10/2020Leap TherapeuticsRobert W. BairdInitiated Coverage
3/23/2021Aprea TherapeuticsRoyal Bank of CanadaLower Price Target
12/29/2020Aprea TherapeuticsMorgan StanleyLower Price Target
12/16/2020Aprea TherapeuticsBerenberg BankInitiated Coverage
9/29/2020Aprea TherapeuticsJPMorgan Chase & Co.Initiated Coverage
6/25/2020Moleculin BiotechOppenheimerReiterated Rating
11/18/2019Moleculin BiotechRoth CapitalReiterated Rating
6/3/2019Cyclerion TherapeuticsCredit Suisse GroupInitiated Coverage
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.